The initiation of coverage by Piper Sandler with an Overweight rating and a significantly high price target of $93 suggests a strong bullish outlook for Soleno Therapeutics. This endorsement from a reputable analyst is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price, given the high target set.